Piper Sandler analyst Biren Amin initiated coverage of Perspective Therapeutics (CATX) with an Overweight rating and $16 price target The firm says the company’s pipeline of lead-212 radiotherapies powers alpha radiation with superior potency relative to beta-emitters. Piper sees near-term catalysts for Perspective shares with data updates in mid-2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Buy Rating on Perspective Therapeutics (CATX) Driven by Differentiated Radiopharmaceutical Platform and Undervalued Long-Term Upside
- Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline
- Midday Fly By: Disney slips despite Q1 beat, Devon to combine with Coterra
- Perspective Therapeutics prices 39.58M shares at $3.79 in underwritten offering
- Perspective Therapeutics Highlights Progress in Radiopharmaceutical Pipeline